logo
Procurement rules for scientific research eased

Procurement rules for scientific research eased

Time of India07-06-2025
Mumbai: In a resounding shift, the ministry of finance eased a long-standing bottleneck in procurement rules that once tethered researchers to the govt e-Marketplace (GeM), now allowing them to source scientific equipment and consumables from outside it.
The revision in monetary ceilings and procurement channels, officials say, required the direct intervention of Prime Minister Narendra Modi.
For the scientific community, this isn't just administrative reform—it's an acknowledgment and a huge relief. "Science cannot be caged in platforms and progress cannot always be L1," said a frustrated scientist, who said procurement was running into long delays because of cost and quality issues.
The spirit behind GeM portal is, in principle, noble, said most scientists—designed to uplift Indian suppliers and foster a self-reliant manufacturing ecosystem.
"But behind the digital veneer of transparency and procurement lies a troubling reality."
"As a scientist, I ask—what truly serves the nation? If I want to order a computer that serves my requirements today, I cannot buy one unless it is L1," said professor at the School of Biotechnology at Jawaharlal Nehru University, Binay Panda.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
The Most Successful Way of Intraday Trading is "Market Profile"
TradeWise
Learn More
Undo
Five amendments have been made to existing procurement rules. Vice-Chancellors and directors of India's top scientific and academic institutions no longer have to wait for clearances to procure scientific equipment and consumables for research. Under the newly eased rules, they now hold the power to approve Global Tender Enquiries—up to a staggering Rs 200 crore—if they believe the need is justified. No central nod, no extra scrutiny.
Just their judgment.
Similarly, the ceiling for direct purchases—those made without quotations—has been raised from Rs 1 lakh to Rs 2 lakh. And what once required a drawn-out trail of tenders—purchases from Rs 1 to 10 lakh—can now be cleared by a purchase committee for anything up to Rs 25 lakh. Additionally, the limits on limited tender enquiry have been lifted—from Rs 50 lakh to Rs 1 crore. And perhaps, most telling of all, said scientists—the need for open tenders—earlier triggered at Rs 50 lakh—will now apply only to purchases above Rs 1 crore.
Minister of State for Science and Technology, Jitendra Singh, took to social media and termed this as "a landmark step" for enabling #EaseOfDoingResearch. "This will reduce delays, also enhance autonomy and flexibility for research institutions—empowering them to innovate faster," he added. Secretary of the Department of Science and Technology, Prof Abhay Karandikar, said, "It was made possible by the collective efforts of everyone, including other scientific secretaries, PSA, Department of Expenditure and Cabinet Secretariat.
"
Another scientist explained that in this "algorithm-driven marketplace, the lowest bidder always wins, never mind if the product fails the test of quality. What use is cost-efficiency if it sacrifices precision and most importantly, the requirements of a scientific experiment? What use is patriotism if it's only glued on?"
"They don't really make these products here," added Prof Panda. "They import many parts, assemble them locally, and slap on a Make in India sticker—as if that alone sanctifies the machine." He quickly added, "If there is a good Indian product, we do not think twice. We prefer make-in-India by default—it's more affordable, support is better, and it's close by." Most scientists echoed this. However, "We don't want to buy an Indian product if science suffers.
"
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI171 crash: Probe pending in India, new US aviation regulator boss rules out fuel switch glitch
AI171 crash: Probe pending in India, new US aviation regulator boss rules out fuel switch glitch

First Post

time3 minutes ago

  • First Post

AI171 crash: Probe pending in India, new US aviation regulator boss rules out fuel switch glitch

Commenting on the devastating Air India plane crash, the new head of the US's Federal Aviation Authority (FAA), Bryan Bedford, dismissed the possibility of an inadvertent movement of the aircraft's fuel control switch. read more The wreckage of the Air India plane that crashed moments after taking off from the Ahmedabad airport, lies on a building, in Ahmedabad. Both switches feeding fuel to the two engines of Air India flight 171 were cut off followed before the plane crashed in Ahmedabad, seconds after taking off, the first investigation report into the crash has revealed. PTI As the investigation into the Air India 171 plane crash continues, the new head of the US Federal Aviation Administration (FAA) ruled out mechanical issues as the cause behind the crash in Ahmedabad. The new FAA boss went on to suggest that the fuel control switches on the doomed AI 171 were manually moved, hinting at a pilot error. In a statement on the matter, FAA Administrator Bryan Bedford dismissed the possibility of an inadvertent movement of the aircraft's fuel control switch. STORY CONTINUES BELOW THIS AD 'We can say with a high level of confidence it doesn't appear to be a mechanical issue with the Boeing fuel control unit. We feel very comfortable that this isn't an issue with inadvertent manipulation of fuel control,' Reuters quoted FAA administrator Bryan Bedford as saying. Meanwhile, Indian authorities, who are currently investigating the matter, requested patience for the final report. They urged both the public and experts to refrain from drawing conclusions and did not comment on Bedford's recent remarks. The matter is still under investigation As per the preliminary report released by India's Aircraft Accident Investigation Bureau (AAIB), the Boeing 787-8 Dreamliner's fuel supply to engines had been cut off, causing it to crash. While it is not concluded what caused the fuel switches' position to change, soon after the report was released, Western media started alluding to a pilot error. In the report, it was also mentioned that the cockpit voice recording revealed that one pilot asked the other why he had moved the switches, to which the latter replied he hadn't. In light of this, several Western news outlets started speculating about the mental health of the pilots and started to report more about their personal lives. Amid the chaos, Boeing is maintaining a cautious stance on the matter. Reacting to Bedford's statement, Boeing said: 'We'll defer to the FAA for any comments on this.' According to Reuters, the FAA chief made the remarks while he was speaking to reporters on the sidelines of an air show in Wisconsin. In support of this assertion, Bedford cited an evaluation conducted by FAA employees who had 'taken the units out, tested them and had inspectors get on aircraft and review them'. STORY CONTINUES BELOW THIS AD

Not covered in FTA, carbon tax may spoil in India-UK free trade mood; here's why
Not covered in FTA, carbon tax may spoil in India-UK free trade mood; here's why

First Post

time3 minutes ago

  • First Post

Not covered in FTA, carbon tax may spoil in India-UK free trade mood; here's why

Britain's proposed Carbon Border Adjustment Mechanism (CBAM) is not included in the FTA with India because London has not yet formally notified the tax. read more The free trade agreement between India and the UK does not cover Britain's proposed Carbon Border Adjustment Mechanism (CBAM). However, officials stated on Friday (July 25) that if such a tax is introduced later, India will have the right to take measures to offset its impact on domestic exports, reported Economic Times. The CBAM is not included in the agreement because Britain has not yet formally notified the tax. In December 2023, the UK announced plans to implement the CBAM starting in 2027. STORY CONTINUES BELOW THIS AD The issue was raised during negotiations for the Comprehensive Economic and Trade Agreement (CETA). 'If it is implemented and negates the trade benefits of India under the agreement, India will have the freedom to rebalance it. We can take counterbalancing measures. This much understanding has been made in the form of note verbale,' an official was quoted as saying by the ET.. A note verbale refers to a diplomatic communication exchanged between two countries. 'There is an understanding that in case the UK make it effective against India in future, then we will also have the right to take counterbalance measures… India can take away the concessions and there will be a mechanism for that,' the official further noted. India is also engaged in discussions with the European Union, which is planning its own CBAM. The two parties are negotiating a trade agreement, expected to be finalised this year. India has labelled the CBAM as a trade barrier. A carbon tax is considered a non-tariff barrier. The European Union has already implemented such a tax on imports exceeding a specific carbon emission threshold. For every tonne of excess carbon emission, a levy ranging from €1 to €100 per tonne is imposed. India and the United Kingdom (UK) signed the Free Trade Agreement (FTA) on Thursday (July 24) during PM Narendra Modi's visit to the UK. STORY CONTINUES BELOW THIS AD New Delhi and London concluded talks in May to reach a bilateral Free Trade Agreement, discussions for which first began in January 2022. As per the British government estimates, the FTA will boost its GDP by £4.8 billion ($6.5 billion) annually. Indian exports to the UK are expected to double by 2030.

India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister

India.com

time3 minutes ago

  • India.com

India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister

New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store